$75.92
1.33% day before yesterday
Nasdaq, Dec 06, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$75.92
-5.03 6.21% 1M
+17.51 29.98% 6M
+13.13 20.91% YTD
+20.50 36.99% 1Y
+10.91 16.78% 3Y
-18.56 19.64% 5Y
-1.31 1.69% 10Y
Nasdaq, Closing price Fri, Dec 06 2024
+1.00 1.33%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $14.63b
Enterprise Value $12.89b
P/E (TTM) P/E ratio 537.68
EV/FCF (TTM) EV/FCF 419.80
EV/Sales (TTM) EV/Sales 3.16
P/S ratio (TTM) P/S ratio 3.59
P/B ratio (TTM) P/B ratio 4.62
Revenue growth (TTM) Revenue growth 12.94%
Revenue (TTM) Revenue $4.08b
EBIT (operating result TTM) EBIT $-12.09m
Free Cash Flow (TTM) Free Cash Flow $30.70m
Cash position $1.77b
EPS (TTM) EPS $0.14
P/E forward 200.35
P/S forward 3.48
EV/Sales forward 3.06
Short interest 6.46%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Incyte forecast:

13x Buy
46%
14x Hold
50%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Incyte forecast:

Buy
46%
Hold
50%
Sell
4%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,076 4,076
13% 13%
100%
- Direct Costs 358 358
19% 19%
9%
3,717 3,717
12% 12%
91%
- Selling and Administrative Expenses 1,056 1,056
5% 5%
26%
- Research and Development Expense 2,585 2,585
53% 53%
63%
76 76
88% 88%
2%
- Depreciation and Amortization 88 88
12% 12%
2%
EBIT (Operating Income) EBIT -12 -12
102% 102%
0%
Net Profit 32 32
92% 92%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
about 22 hours ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC.
Neutral
Business Wire
one day ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Business Wire
12 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follo...
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,524
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today